Select Vaccines partner ships hep E kits to hotspot
Wednesday, 08 September, 2004
Select Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
The kits, which were provided to the WHO on a humanitarian basis, will be used in the Darfur region of Sudan to help contain an outbreak of hepatitis E in the refugee camps. Select Vaccines licensed the hepatitis E rapid diagnostic kit, as well as a laboratory diagnostic to Genelabs for a 12-year term in August, in return for upfront payments and royalties.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
